Source: Pharamceutical Technology

Affini-T: AFNT-211 by Affini-T Therapeutics for Colorectal Cancer: Likelihood of Approval

AFNT-211 is under clinical development by Affini-T Therapeutics and currently in Phase II for Colorectal Cancer.

Read full article »
Affini-T's Competitors | Affini-T's News | Affini-T's Financials
Stay up-to-date with the latest news on Affini-T
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Jak Knowles's photo - Co-Founder & CEO of Affini-T

Co-Founder & CEO

Jak Knowles

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Affini-T